Face Lesions in En Coup De Sabre Scleroderma in Children: Modern Treatment and Outcomes Improvement
https://doi.org/10.15690/vsp.v21i5.2460
Abstract
Localized scleroderma (LS) is an inflammatory sclerosing disease of the skin and subcutaneous tissues associated with its atrophy. Commonly, LS is a benign self-limited disease, although, the chronic form of this disease is recurrent. Particular attention is paid to the research of treatments methods that could eliminate not only immune-mediated mechanisms, but also its outcomes (such as gross cosmetic defects on the face), which negatively affect child’s physical and psycho-emotional development. Recently, fat transplantation efficacy has been studied as it can restore the volume and improve skin quality. This article presents the results of such surgery in a patient (15 years old) with linear form of LS.
Supporting agencies: Not specified
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, LEO Pharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma
Alena A. Savelova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests.
Alina R. Misbakhova
Institute of Plastic Surgery and Cosmetology
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests
References
1. Li SC, Feldman BM, Higgins GC, et al. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol. 2018;37(1):175–181. doi: https://doi.org/10.3899/jrheum.090708
2. Jablonska S, Blaszczyk M. Long-lasting follow-up favours a close relationship between progressive facial hemiatrophy and scleroderma en coup de sabre. J Eur Acad Dermatol Venereol. 2019;19(4): 403–404. doi: https://doi.org/10.1111/j.1468-3083.2005.00979.x
3. Zhao M, Wu J, Wu H, et al. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Clin Rev Allergy Immunol. 2022;62(2):273–291. doi: https://doi.org/10.1007/s12016-020-08831-4
4. Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018; 65(4):757–781. doi: https://doi.org/10.1016/j.pcl.2018.04.002
5. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9): 2873–2681. doi: https://doi.org/10.1002/art.21264
6. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–396. doi: https://doi.org/10.1016/j.jaad.2008.05.005
7. Tollefson M, Witman P. En coup de sabre morphea and Parry– Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257–263. doi: https://doi.org/10.1016/j.jaad.2006.10.959
8. Jun JH, Kim HY, Jung HJ, et al. Parry–Romberg Syndrome with En Coup de Sabre. Ann Dermatol. 2011;23(3):342–347. doi: https://doi.org/10.5021/ad.2011.23.3.342
9. Orozco‐Covarrubias L, Guzmán-Meza A, Ridaura-Sanz C, et al. Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them? J Eur Acad Dermatol Venereol. 2002;16(4): 361. doi: https://doi.org/10.1046/j.1468-3083.2002.00442.x
10. Tolkachjov SN, Patel NG, Tollefson MM. Progressive hemi facial atrophy: a review. Orphanet J Rare Dis. 2015;10:39. doi: https://doi.org/10.1186/s13023-015-0250-9
11. Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213–218. doi: https://doi.org/10.1002/acr.20070
12. Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of Pediatric Localized Scleroderma. Front Immunol. 2019;10:908. doi: https://doi.org/10.3389/fimmu.2019.00908
13. Budzynska-Wlodarczyk J, Michalska-Jakubus MM, Kowal M, Krasowska D. Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma. Postepy Dermatol Alergol. 2020;33(1):47–51. doi: https://doi.org/10.5114/pdia.2015.48044
14. Torok KS. Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am. 2012;59(2):381–405. doi: https://doi.org/10.1016/j.pcl.2012.03.011
15. Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity Index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36(12):2819–2829. doi: https://doi.org/10.3899/jrheum.081284
16. Al-Himdani S, Jessop ZM, Al-Sabah A, et al. Tissue-engineered solutions in plastic and reconstructive surgery: principles and practice. Front Surg. 2017;4:4. doi: https://doi.org/10.3389/fsurg.2017.00004
17. Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–1156. doi: https://doi.org/10.1016/j.jaad.2012.03.036
18. Saxton-Daniels S, Jacobe HT. An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Derm atol. 2019;146(9):1044–1045. doi: https://doi.org/10.1001/archdermatol
19. Kroft EB, Berkhof NJ, van de Kerkhof PC, et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol. 2008;59(6):1017–1030. doi: https://doi.org/10.1016/j.jaad.2008.07.042
Review
For citations:
Murashkin N.N., Savelova A.A., Misbakhova A.R. Face Lesions in En Coup De Sabre Scleroderma in Children: Modern Treatment and Outcomes Improvement. Current Pediatrics. 2022;21(5):414-418. (In Russ.) https://doi.org/10.15690/vsp.v21i5.2460
Views:
750
Email this article 
